An enforcement action that might be taken for non-compliance with pharmaceutical regulations is: Response:

Question

Options

• AAn increase in product pricing.
• BAn expansion of market reach.
• CA warning letter.
• DAn endorsement deal.

• A
  8% (2)
• B
  4% (1)
• C
  83% (20)
• D
  4% (1)

Explanation

A warning letter is a formal enforcement tool used by regulatory agencies (such as the FDA) to notify a company of violations of pharmaceutical regulations, requiring corrective action before more severe penalties - such as product seizures, injunctions, or criminal prosecution - are applied.

• A (price increase) is wrong because pricing is a business decision, not a regulatory enforcement mechanism.
• B (market expansion) is the opposite of enforcement - non-compliance typically restricts market access, not expands it.
• D (endorsement deal) is a marketing/commercial concept entirely unrelated to regulatory enforcement.

Memory tip: Think of enforcement actions as having escalating consequences - warning letters are the regulatory "first strike," a formal written notice that puts the company on record. If you remember that enforcement = consequences, you can quickly eliminate anything that sounds like a reward or benefit (expansion, endorsement, higher pricing power).

No community discussion yet for this question.